☆ 4.5 Article

Lights and Shadows of Cerebrospinal Fluid Biomarkers in the Current Alzheimer's Disease Framework

JOURNAL OF ALZHEIMERS DISEASE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Neurosciences

The probabilistic model of Alzheimer disease: the amyloid hypothesis revised

Giovanni B. Frisoni et al.

Summary: The amyloid hypothesis has long been the leading model for the pathogenesis of Alzheimer's disease, but a probabilistic model is proposed as an alternative due to the increasing understanding of the complex biology of Alzheimer's disease. This new model suggests that genetic factors, environmental exposures, and lower-risk genes play significant roles in different types of Alzheimer's disease, leading to a better understanding of disease pathophysiology and potentially accelerating the development of prevention and treatment strategies.

NATURE REVIEWS NEUROSCIENCE (2022)

添加到收藏夹

Review Neurosciences

The synaptic marker neurogranin as a disease state biomarker in Alzheimer's disease: a systematic review and meta-analysis

Zhibin Wang et al.

Summary: The study suggests that CSF Ng levels are more apparent in AD and MCI compared to control populations, and can discriminate between AD and MCI from control populations. This indicates that synaptic degeneration worsens as patients progress from MCI to AD.

INTERNATIONAL JOURNAL OF NEUROSCIENCE (2022)

添加到收藏夹

Review Cell Biology

Female specific risk factors for the development of Alzheimer's disease neuropathology and cognitive impairment: Call for a precision medicine approach

Chinedu Udeh-Momoh et al.

Summary: Alzheimer's disease may manifest changes in midlife, with sex potentially influencing cognition and brain health. This review discusses sex-differences in AD neuropathological burden and outlines potential endocrinological mechanisms, providing recommendations for targeted research on female-specific risk factors.

AGEING RESEARCH REVIEWS (2021)

添加到收藏夹

Review Biology

A review on omics-based biomarkers discovery for Alzheimer's disease from the bioinformatics perspectives: Statistical approach vs machine learning approach

Mei Sze Tan et al.

Summary: Alzheimer's Disease is a common neurodegenerative disease affecting cognition, with increasing incidence as the elderly population grows. Diagnosis is based on clinical criteria including patient history, physical examination, neuropsychological testing and appropriate investigations. Omics techniques may aid in diagnosis and exploration of disease development mechanisms.

COMPUTERS IN BIOLOGY AND MEDICINE (2021)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers

N. J. Ashton et al.

Summary: The development of blood biomarkers for Alzheimer's disease has shown promise for dementia diagnosis and early detection. Plasma p-tau has demonstrated analytical and clinical validity, while A beta's maturity level remains partially achieved. Despite progress in phases 1 through 3, more data is needed on covariate effects on biomarker measurement.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework

E. E. Wolters et al.

Summary: The maturity of [F-18]flortaucipir PET in AD biomarkers has been assessed based on the AD Biomarker Roadmap, showing high affinity and excellent discriminative accuracy for AD. However, further research is needed to fully establish its early detection ability and clinical utility.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

A. Leuzy et al.

Summary: By utilizing the Biomarker Roadmap methodology, experts assessed the maturity levels of CSF AD biomarkers in 2019 and found significant advancements in a unified protocol for CSF handling, introduction of certified reference methods for A beta 42, and fully automated assays. While progress has been made in phases one through three, further work is needed in phases four and five to assess real world performance and impact/cost.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

Gerard N. Bischof et al.

Summary: The validation of second-generation tau PET tracers has passed the analytical phase of the strategic biomarker roadmap, with studies showing evidence of superiority over first-generation tracers. However, research on clinical validity is still ongoing.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update

Marina Boccardi et al.

Summary: This study revises and updates the 2017 AD Biomarker Roadmap to better evaluate existing evidence and implement AD biomarkers. The revised methodology allows for more diverse study designs and reference standards, enabling researchers to assess evidence transparently and systematically.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Article Medicine, General & Internal

Donanemab in Early Alzheimer's Disease

Mark A. Mintun et al.

Summary: In this study, donanemab showed improved composite scores for cognition and daily living activities compared to placebo in patients with early Alzheimer's disease at 76 weeks, although secondary outcomes varied. Longer and larger trials are needed to further explore the efficacy and safety of donanemab in Alzheimer's disease.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medical Laboratory Technology

The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis

Kristopher M. Kirmess et al.

Summary: The PrecivityAD (TM) test developed by C2N quantifies A beta isoforms and APOE isoform-specific proteotyping accurately and with high precision. The results show that the test is sensitive, linear over a wide analytical range, free from significant interferences, and suitable for use in clinical laboratories.

CLINICA CHIMICA ACTA (2021)

添加到收藏夹

Article Neurosciences

A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

Tim West et al.

Summary: The development of a high-resolution mass spectrometry-based plasma biomarker test shows strong diagnostic performance in distinguishing brain amyloid status for Alzheimer's disease and may enhance the efficiency of enrolling participants into AD drug trials.

MOLECULAR NEURODEGENERATION (2021)

添加到收藏夹

Article Clinical Neurology

An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer's disease

Christopher Clark et al.

Summary: By integrating multi-omics approaches, this study identified novel molecular and pathway alterations associated with Alzheimer's disease pathology. The findings revealed multiple interactions between single 'omics modalities and distinct multi-omics molecular signatures related to amyloid pathology, neuronal injury, and tau hyperphosphorylation. Pathway enrichment analysis highlighted overrepresentation of hemostasis, immune response, and extracellular matrix signaling pathways in association with AD, while combinations of specific molecules improved prediction of AD pathology and cognitive decline.

ALZHEIMERS RESEARCH & THERAPY (2021)

添加到收藏夹

Review Clinical Neurology

Critical Appraisal of Amyloid Lowering Agents in AD

Boris Decourt et al.

Summary: According to the amyloid cascade hypothesis, removing amyloid beta (A beta) is believed to cure Alzheimer's disease (AD), but current clinical trials lack definitive efficacy. Therefore, research has shifted focus towards immunotherapy, particularly monoclonal antibody therapies targeting A beta plaques. This approach offers potential for treating different stages of AD and may provide valuable insights into the trajectory of drug development for neurodegenerative diseases.

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2021)

添加到收藏夹

Article Neurosciences

Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies

Andrea Pilotto et al.

Summary: The study found that plasma NfL levels were higher in DLB patients and emerged as the best predictor of cognitive decline. Plasma NfL may become a useful prognostic biomarker in the early stages of DLB.

JOURNAL OF ALZHEIMERS DISEASE (2021)

添加到收藏夹

Editorial Material Clinical Neurology

Glial fibrillary acidic protein: a blood biomarker to differentiate neurodegenerative from psychiatric diseases

Henrik Zetterberg

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2021)

添加到收藏夹

Article Clinical Neurology

Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group

Bruno Dubois et al.

Summary: The use of biomarkers in the diagnosis of Alzheimer's disease has limitations and should be used cautiously in a clinical setting, restricted to individuals with specific phenotypes and positive biomarkers. Biomarker-positive cognitively unimpaired individuals should be considered at-risk for progression to Alzheimer's disease.

LANCET NEUROLOGY (2021)

添加到收藏夹

Review Medicine, General & Internal

Cognitive reserve and Alzheimer's biological continuum: clues for prediction and prevention of dementia

Alessandro Martorana et al.

Summary: Cognitive reserve is a concept that involves individual abilities to cope with changes, and it can help predict and prevent cognitive decline and Alzheimer's disease. By maintaining environmental enrichment, efficient synaptic plasticity mechanisms can protect cognitive reserve, keeping repair mechanisms effective and promoting successful aging.

MINERVA MEDICA (2021)

添加到收藏夹

Article Clinical Neurology

Developing the ATX(N) classification for use across the Alzheimer disease continuum

Harald Hampel et al.

Summary: Breakthroughs in highly accurate fluid and neuroimaging biomarkers have transformed the conceptual approach to Alzheimer's disease from symptom-based to a clinical-biological construct. The AT(N) and evolving ATX(N) systems play crucial roles in categorizing individuals and potential applications in clinical trials and future practice. Current challenges include validation, standardization, and real-world application of these systems.

NATURE REVIEWS NEUROLOGY (2021)

添加到收藏夹

Article Neurosciences

Anti-Cholinergic Derangement of Cortical Metabolism on 18F-FDG PET in a Patient with Frontotemporal Lobar Degeneration Dementia: A Case of the TREDEM Registry

Maurizio Gallucci et al.

JOURNAL OF ALZHEIMERS DISEASE (2020)

添加到收藏夹

Review Health Care Sciences & Services

Use of Biomarkers in Ongoing Research Protocols on Alzheimer's Disease

Marco Canevelli et al.

JOURNAL OF PERSONALIZED MEDICINE (2020)

添加到收藏夹

Review Medicine, General & Internal

Dementia prevention, intervention, and care: 2020 report of the Lancet Commission

Gill Livingston et al.

LANCET (2020)

添加到收藏夹

Article Clinical Neurology

Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease

Samantha Budd Haeberlein et al.

Alzheimers & Dementia (2020)

添加到收藏夹

Review Clinical Neurology

Alzheimer's disease: from basic science to precision medicine approach

Gianluigi Forloni

BMJ NEUROLOGY OPEN (2020)

添加到收藏夹

Review Biotechnology & Applied Microbiology

The role of gut microbiota in pathogenesis of Alzheimer's disease

M. Bostanciklioglu

JOURNAL OF APPLIED MICROBIOLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease

Niklas Mattsson et al.

JAMA NEUROLOGY (2019)

添加到收藏夹

Article Neurosciences

Overlap Between Frontotemporal Dementia and Dementia with Lewy Bodies: A Treviso Dementia (TREDEM) Registry Case Report

Maurizio Gallucci et al.

JOURNAL OF ALZHEIMERS DISEASE (2019)

添加到收藏夹

Article Clinical Neurology

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

Suzanne E. Schindler et al.

NEUROLOGY (2019)

添加到收藏夹

Review Geriatrics & Gerontology

Methodological Issues in the Clinical Validation of Biomarkers for Alzheimer's Disease: The Paradigmatic Example of CSF

Marco Canevelli et al.

FRONTIERS IN AGING NEUROSCIENCE (2019)

添加到收藏夹

Review Clinical Neurology

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

Clifford R. Jack et al.

ALZHEIMERS & DEMENTIA (2018)

添加到收藏夹

Review Rheumatology

Biomarkers as drug development tools: discovery, validation, qualification and use

Virginia B. Kraus

NATURE REVIEWS RHEUMATOLOGY (2018)

添加到收藏夹

Review Clinical Neurology

Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic

Harald Hampel et al.

NATURE REVIEWS NEUROLOGY (2018)

添加到收藏夹

Article Neurosciences

The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: The Italian Selfie

Giulia M. Sancesario et al.

JOURNAL OF ALZHEIMERS DISEASE (2017)

添加到收藏夹

Article Neurosciences

Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia

Ron L. H. Handels et al.

JOURNAL OF ALZHEIMERS DISEASE (2017)

添加到收藏夹

Article Geriatrics & Gerontology

The biomarker-based diagnosis of Alzheimer's disease. 2-lessons from oncology

Marina Boccardi et al.

NEUROBIOLOGY OF AGING (2017)

添加到收藏夹

Article Geriatrics & Gerontology

Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Valentina Garibotto et al.

NEUROBIOLOGY OF AGING (2017)

添加到收藏夹

Article Geriatrics & Gerontology

Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Konstantinos Chiotis et al.

NEUROBIOLOGY OF AGING (2017)

添加到收藏夹

Article Geriatrics & Gerontology

Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Mara ten Kate et al.

NEUROBIOLOGY OF AGING (2017)

添加到收藏夹

Article Geriatrics & Gerontology

Clinical validity of presynaptic dopaminergic imaging with 123I- ioflupane and noradrenergic imaging with 123I- MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework

Ida Sonni et al.

NEUROBIOLOGY OF AGING (2017)

添加到收藏夹

Article Geriatrics & Gerontology

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

Niklas Mattsson et al.

NEUROBIOLOGY OF AGING (2017)

添加到收藏夹

Review Clinical Neurology

Microbiota and neurodegenerative diseases

Moira Marizzoni et al.

CURRENT OPINION IN NEUROLOGY (2017)

添加到收藏夹

Article Clinical Neurology

Consensus classification of posterior cortical atrophy

Sebastian J. Crutch et al.

ALZHEIMERS & DEMENTIA (2017)

添加到收藏夹

Article Multidisciplinary Sciences

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

Jeff Sevigny et al.

NATURE (2016)

添加到收藏夹

Review Clinical Neurology

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

Clifford R. Jack et al.

NEUROLOGY (2016)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Current Thinking on the Mechanistic Basis of Alzheimer's and Implications for Drug Development

C. Ising et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)

添加到收藏夹

Article Neurosciences

Cost-Effectiveness of the Use of Biomarkers in Cerebrospinal Fluid for Alzheimer's Disease

Cristina Valcarcel-Nazco et al.

JOURNAL OF ALZHEIMERS DISEASE (2014)

添加到收藏夹

Review Clinical Neurology

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

Bruno Dubois et al.

LANCET NEUROLOGY (2014)

添加到收藏夹

Article Clinical Neurology

Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium

Maria C. Carrillo et al.

ALZHEIMERS & DEMENTIA (2013)

添加到收藏夹

Review Chemistry, Medicinal

A review on cholinesterase inhibitors for Alzheimer's disease

Preet Anand et al.

ARCHIVES OF PHARMACAL RESEARCH (2013)

添加到收藏夹

Review Medicine, Research & Experimental

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42

Niklas Mattsson et al.

BIOMARKERS IN MEDICINE (2012)

添加到收藏夹

Article Clinical Neurology

Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Reisa A. Sperling et al.

ALZHEIMERS & DEMENTIA (2011)

添加到收藏夹

Article Clinical Neurology

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Guy M. McKhann et al.

ALZHEIMERS & DEMENTIA (2011)

添加到收藏夹

Article Clinical Neurology

The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Marilyn S. Albert et al.

ALZHEIMERS & DEMENTIA (2011)

添加到收藏夹

Review Clinical Neurology

Classification of primary progressive aphasia and its variants

M. L. Gorno-Tempini et al.

NEUROLOGY (2011)

添加到收藏夹

Article Clinical Neurology

Revising the definition of Alzheimer's disease: a new lexicon

Bruno Dubois et al.

LANCET NEUROLOGY (2010)

添加到收藏夹

Review Clinical Neurology

Research criteria for the diagnosis of Alzheimers disease: revising the NINCDS-ADRDA criteria

Bruno Dubois et al.

LANCET NEUROLOGY (2007)

添加到收藏夹

Article Medicine, General & Internal

Evidence base of clinical diagnosis - The architecture of diagnostic research

DL Sackett et al.

BRITISH MEDICAL JOURNAL (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.